Relay Therapeutics - RLAY Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $21.11
  • Forecasted Upside: 223.29%
  • Number of Analysts: 10
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 9 Buy Ratings
  • 0 Strong Buy Ratings
$6.53
▲ +0.04 (0.62%)

This chart shows the closing price for RLAY by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Relay Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for RLAY and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for RLAY

Analyst Price Target is $21.11
▲ +223.29% Upside Potential
This price target is based on 10 analysts offering 12 month price targets for Relay Therapeutics in the last 3 months. The average price target is $21.11, with a high forecast of $28.00 and a low forecast of $16.00. The average price target represents a 223.29% upside from the last price of $6.53.

This chart shows the closing price for RLAY for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 10 contributing investment analysts is to moderate buy stock in Relay Therapeutics. This rating changed within the last month from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 7 buy ratings
  • 1 hold ratings
  • 1 sell ratings
4/13/2023
  • 1 strong buy ratings
  • 5 buy ratings
  • 2 hold ratings
  • 0 sell ratings
7/12/2023
  • 1 strong buy ratings
  • 7 buy ratings
  • 2 hold ratings
  • 0 sell ratings
10/10/2023
  • 1 strong buy ratings
  • 7 buy ratings
  • 2 hold ratings
  • 0 sell ratings
1/8/2024
  • 1 strong buy ratings
  • 7 buy ratings
  • 2 hold ratings
  • 0 sell ratings
4/7/2024
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/6/2024
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/4/2024
  • 0 strong buy ratings
  • 9 buy ratings
  • 1 hold ratings
  • 0 sell ratings
10/4/2024

Latest Recommendations

  • 0 strong buy ratings
  • 9 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
9/17/2024JMP SecuritiesReiterated RatingMarket Outperform ➝ Market Outperform$21.00 ➝ $21.00
9/16/2024Stifel NicolausReiterated RatingBuy ➝ Buy$28.00 ➝ $28.00
9/16/2024HC WainwrightBoost TargetBuy ➝ Buy$18.00 ➝ $19.00
9/10/2024Bank of AmericaBoost TargetBuy ➝ Buy$20.00 ➝ $24.00
9/10/2024BarclaysBoost TargetOverweight ➝ Overweight$14.00 ➝ $17.00
9/10/2024JPMorgan Chase & Co.Lower TargetOverweight ➝ Overweight$23.00 ➝ $21.00
9/10/2024The Goldman Sachs GroupInitiated CoverageBuy$20.00
9/10/2024OppenheimerDowngradeOutperform ➝ Market Perform
9/10/2024Jefferies Financial GroupUpgradeHold ➝ Buy$10.60 ➝ $16.00
8/7/2024JPMorgan Chase & Co.Lower TargetOverweight ➝ Overweight$29.00 ➝ $23.00
8/7/2024OppenheimerLower TargetOutperform ➝ Outperform$25.00 ➝ $24.00
7/26/2024BarclaysLower TargetOverweight ➝ Overweight$15.00 ➝ $14.00
7/18/2024JMP SecuritiesLower TargetMarket Outperform ➝ Market Outperform$24.00 ➝ $21.00
7/17/2024HC WainwrightLower TargetBuy ➝ Buy$20.00 ➝ $18.00
6/7/2024HC WainwrightReiterated RatingBuy ➝ Buy$20.00 ➝ $20.00
5/10/2024BarclaysUpgradeEqual Weight ➝ Overweight$15.00 ➝ $15.00
5/6/2024JMP SecuritiesReiterated RatingMarket Outperform ➝ Market Outperform$24.00
5/6/2024OppenheimerReiterated RatingOutperform ➝ Outperform$33.00 ➝ $25.00
2/22/2024Leerink PartnrsReiterated RatingOutperform
2/22/2024Stifel NicolausBoost TargetBuy ➝ Buy$25.00 ➝ $30.00
12/11/2023HC WainwrightLower TargetBuy ➝ Buy$19.00 ➝ $17.00
11/8/2023HC WainwrightLower TargetBuy ➝ Buy$33.00 ➝ $19.00
10/17/2023HC WainwrightBoost TargetBuy ➝ Buy$30.00 ➝ $33.00
8/17/2023HC WainwrightLower TargetBuy ➝ Buy$32.00 ➝ $30.00
8/9/2023OppenheimerReiterated RatingOutperform ➝ Outperform$33.00
8/8/2023Leerink PartnrsReiterated RatingOutperform
8/8/2023SVB SecuritiesInitiated CoverageOutperform
6/9/2023HC WainwrightLower Target$46.00 ➝ $32.00
5/5/2023JMP SecuritiesLower Target$28.00 ➝ $24.00
4/20/2023Stifel NicolausLower TargetBuy$38.00 ➝ $34.00
4/20/2023Jefferies Financial GroupUpgradeUnderperform ➝ Hold$16.00 ➝ $12.50
4/19/2023JMP SecuritiesReiterated RatingMarket Outperform$28.00
4/19/2023JPMorgan Chase & Co.Lower TargetOverweight$42.00 ➝ $29.00
4/19/2023Raymond JamesUpgradeOutperform ➝ Strong-Buy$29.00
4/19/2023BarclaysLower TargetEqual Weight$23.00 ➝ $15.00
4/18/2023OppenheimerReiterated RatingOutperform$33.00
4/12/2023Raymond JamesInitiated CoverageOutperform ➝ Outperform$29.00
4/5/2023JPMorgan Chase & Co.Lower TargetOverweight$45.00 ➝ $42.00
3/9/2023GuggenheimLower Target$45.00 ➝ $28.00
3/7/2023HC WainwrightBoost TargetBuy$43.00 ➝ $46.00
2/2/2023OppenheimerInitiated CoverageOutperform$33.00
1/19/2023JMP SecuritiesLower TargetMarket Outperform$38.00 ➝ $28.00
11/7/2022HC WainwrightLower TargetBuy$50.00 ➝ $43.00
9/30/2022BarclaysInitiated CoverageEqual Weight$23.00
9/14/2022JMP SecuritiesBoost TargetMarket Outperform$35.00 ➝ $38.00
9/12/2022HC WainwrightBoost TargetBuy$46.00 ➝ $50.00
9/1/2022Stifel NicolausInitiated CoverageBuy$40.00
8/9/2022HC WainwrightLower TargetBuy$47.00 ➝ $46.00
6/6/2022Jefferies Financial GroupInitiated CoverageUnderperform$13.00
5/24/2022The Goldman Sachs GroupLower TargetBuy$49.00 ➝ $42.00
5/10/2022HC WainwrightLower Target$54.00 ➝ $47.00
5/9/2022JMP SecuritiesLower Target$50.00 ➝ $35.00
2/1/2022Berenberg BankInitiated CoverageBuy$45.00
1/3/2022GuggenheimLower Target$52.00 ➝ $45.00
10/8/2021JPMorgan Chase & Co.UpgradeBuy$51.00
10/4/2021JMP SecuritiesReiterated RatingBuy$50.00
8/17/2021HC WainwrightLower TargetBuy$57.00 ➝ $54.00
7/21/2021Bank of AmericaInitiated CoverageBuy$50.00
3/29/2021JMP SecuritiesBoost TargetAverage ➝ Outperform$50.00 ➝ $66.00
1/29/2021JPMorgan Chase & Co.Boost TargetNeutral$36.00 ➝ $52.00
12/15/2020HC WainwrightReiterated RatingBuy$54.00 ➝ $57.00
12/8/2020JMP SecuritiesInitiated CoverageOutperform$66.00
11/5/2020HC WainwrightInitiated CoverageBuy$54.00
8/10/2020GuggenheimInitiated CoverageBuy$48.00
8/10/2020CowenInitiated CoverageOutperform
8/10/2020JPMorgan Chase & Co.Initiated CoverageNeutral$36.00
8/10/2020The Goldman Sachs GroupInitiated CoverageBuy$64.00
(Data available from 10/4/2019 forward)

News Sentiment Rating

0.57 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 10 very positive mentions
  • 15 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
3/8/2024
  • 2 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/7/2024
  • 6 very positive mentions
  • 7 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
5/7/2024
  • 7 very positive mentions
  • 11 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/6/2024
  • 9 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/6/2024
  • 10 very positive mentions
  • 8 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
8/5/2024
  • 5 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/4/2024
  • 18 very positive mentions
  • 25 positive mentions
  • 4 negative mentions
  • 0 very negative mentions
10/4/2024

Current Sentiment

  • 18 very positive mentions
  • 25 positive mentions
  • 4 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Relay Therapeutics logo
Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and Migoprotafib (GDC-1971), an oral, small molecule, potent and selective inhibitor of the protein tyrosine phosphatase SHP2 that binds and stabilizes Src homology region 2 domain-containing phosphatase-2 (SHP2) as a monotherapy in patients with advanced or metastatic solid tumors. In addition, it has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; and Genentech, Inc. for the development and commercialization of GDC-1971. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Read More

Today's Range

Now: $6.53
Low: $6.38
High: $6.63

50 Day Range

MA: $7.26
Low: $6.24
High: $9.51

52 Week Range

Now: $6.53
Low: $5.70
High: $12.14

Volume

1,262,163 shs

Average Volume

1,449,960 shs

Market Capitalization

$866.81 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.64

Frequently Asked Questions

What sell-side analysts currently cover shares of Relay Therapeutics?

The following Wall Street analysts have issued research reports on Relay Therapeutics in the last twelve months: Bank of America Co., Barclays PLC, HC Wainwright, Jefferies Financial Group Inc., JMP Securities, JPMorgan Chase & Co., Leerink Partnrs, Oppenheimer Holdings Inc., Stifel Nicolaus, and The Goldman Sachs Group, Inc..
View the latest analyst ratings for RLAY.

What is the current price target for Relay Therapeutics?

9 Wall Street analysts have set twelve-month price targets for Relay Therapeutics in the last year. Their average twelve-month price target is $21.11, suggesting a possible upside of 223.3%. Stifel Nicolaus has the highest price target set, predicting RLAY will reach $28.00 in the next twelve months. Jefferies Financial Group Inc. has the lowest price target set, forecasting a price of $16.00 for Relay Therapeutics in the next year.
View the latest price targets for RLAY.

What is the current consensus analyst rating for Relay Therapeutics?

Relay Therapeutics currently has 1 hold rating and 9 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for RLAY.

What other companies compete with Relay Therapeutics?

How do I contact Relay Therapeutics' investor relations team?

Relay Therapeutics' physical mailing address is 399 BINNEY STREET 2ND FLOOR, CAMBRIDGE MA, 02139. The company's listed phone number is 617-370-8837 and its investor relations email address is [email protected]. The official website for Relay Therapeutics is www.relaytx.com. Learn More about contacing Relay Therapeutics investor relations.